Abstract
J Gen Intern Med Published 2012:27(7):863-60. DOI: 10.1007/s11606-011-1966-4 (c) Society of General Internal Medicine 2012 Erratum to: J Gen Intern Med DOI: 10.1007/s11606-011-1966-4 On page 857 of the original publication, the following statement contains a technical error. Recently, the FDA approved Nuedexta, a fixed-dose combination of the cough suppressant dextromethorphan hydrobromide and the antiarrhythmic quinidine sulfate, for treatment of pseudobulbar affect in patients with amyotrophic lateral sclerosis or multiple sclerosis. Correction: Although the FDA approved Nuedexta based on studies in amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), the approved indication was for treatment of pseudobulbar affect (without restriction to a specific underlying condition).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
